JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Esketamine
First Posted Date
2012-07-13
Last Posted Date
2020-06-02
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
30
Registration Number
NCT01640080

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

First Posted Date
2012-07-10
Last Posted Date
2017-03-07
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
12
Registration Number
NCT01636557

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

First Posted Date
2012-06-29
Last Posted Date
2013-06-25
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
86
Registration Number
NCT01631487

A Study of Ketamine in Patients With Treatment-resistant Depression

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Ketamine
First Posted Date
2012-06-26
Last Posted Date
2020-06-02
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
68
Registration Number
NCT01627782

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Ibrutinib
Drug: Ketoconazole
First Posted Date
2012-06-25
Last Posted Date
2013-06-19
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
21
Registration Number
NCT01626651

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Lenalidomide
Drug: Dexamethasone
First Posted Date
2012-06-08
Last Posted Date
2024-10-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
45
Registration Number
NCT01615029

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

First Posted Date
2012-06-04
Last Posted Date
2020-03-03
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
578
Registration Number
NCT01611090

A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics

First Posted Date
2012-05-30
Last Posted Date
2013-04-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
31
Registration Number
NCT01607762

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: Placebo
Drug: Sirukumab
First Posted Date
2012-05-28
Last Posted Date
2018-03-23
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
878
Registration Number
NCT01606761

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: Placebo
Drug: Sirukumab
First Posted Date
2012-05-23
Last Posted Date
2018-01-11
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
1670
Registration Number
NCT01604343
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy